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INTRODUCTION 
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INTRODUCTION 
Anemia is defined as decreased oxygen carrying capacity of blood. 
It is one of the major illness affecting more than 50% of antenatal and 
postnatal women in developing countries like India leading to increased 
maternal mortality and morbidity. Most common type is the nutritional 
anemia – IRON DEFICIENCY ANAEMIA. Menstruation and 
pregnancy put women at a higher risk for anemia. 
 Iron deficiency anemia in pregnant mother is mainly due to 
increased demand or due to poor absorption. This unmet need during 
antenatal period may lead to anemia in postnatal mother. Postnatal 
anemia may also result from acute blood loss during delivery and also 
even due to multiple birth without adequate spacing. 
 WHO defines postnatal anemia as hemoglobin less than 11gm. 
This anemia in postnatal mother may lead to several complications like 
depression, subinvolution of uterus, puerperal infection, sepsis, 
decreased milk production and its quality, lactation failure, deep vein 
thrombosis, poor wound healing and neurocognitive dysfunction in 
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infants. So this postnatal anemia should be diagnosed early and should 
be treated properly to avoid these complications. 
 Postnatal iron deficiency anaemia can be diagnosed clinically 
and confirmed by laboratory parameters like hemoglobin, peripheral 
smear, blood indices and serum ferritin. 
 Various modes of treatment are available to treat postnatal iron 
deficiency anaemia. They are 
 Oral iron 
 Parenteral iron 
 Blood transfusion 
 Due to poor compliance to oral iron and its gastrointestinal side 
effects and because of inherent risks following blood transfusion, 
parenteral iron has gain more importance to treat iron deficiency anaemia 
in clinical practice. Among them second generation intravenous iron 
sucrose is most commonly used. Upcoming is the third generation 
injection ferric carboxymaltose. 
 
  
 
 
AIM OF THE STUDY 
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AIM OF THE STUDY
 This study was conducted to compare the efficacy of ferric 
carboxymaltose and iron sucrose in the treatment of postnatal iron 
deficiency anaemia. 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF 
LITERATURE 
  
4 
 
REVIEW OF LITERATURE 
IRON METABOLISM: 
 It is a unique process where its homeostasis is maintained by 
absorption and not by excretion. Iron is a one way element. When iron 
stores are depleted absorption is increased and when adequate quantity 
of iron is stored absorption is decreased. This is referred to as mucosal 
block of regulation of absorption of iron. Iron is not actively excreted 
from the body, it is eliminated only through epithelial cells from the 
gastrointestinal tract, epidermal cells of skin, and in mensturating women 
red blood cells. The total average body loss of iron is 1-2mg in normal 
adult men and non mensturating women. Although iron is a 
physiological component of sweat only a tiny amount of iron (22.5µg/L) 
is lost by this route. Urinary21 excretion amounts to <0.005 mg/day. 
Mensturating women lose an additionally high variable amount during 
each menstural cycle from 0.006 to more than 0.025 mg/kg/day. 
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IRON DISTRIBUTION: 3 
PROTEIN FUNCTION AMOUNT(g) PERCENT  
Haemoglobin Erythrocyte O₂ 
transport 
2.6 65 
Myoglobin Muscle O₂ storage 0.130 6 
Transferrin Plasma iron transport 0.003 0.1 
Ferritin Intracellular iron 
storage 
0.520 13 
Haemosiderin Intracellular iron 
storage 
0.480 12 
Others(Enzymes)  0.150 3.9 
Catalase peroxidase H₂O₂ degradation   
Cytochromes Electron transport   
Aconitase Tricarboxylic acid   
Ferrochelatase Heme biosynthesis   
Duodenal cytochrome Intestinal iron 
absorption 
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IRON HOMEOSTASIS:  
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IRON REQUIREMENT:            
 Total body iron content is about 3 to 5 gm, out of 
which 75% is in blood, the rest is in liver, bone marrow and muscles. 
Iron is present in all cells 
  
Recommended daily allowance is 20mg out of which only 10% (1-2mg) 
is absorbed. In pregnant and lactating women iron demand increased to 
30- 60 mg. Demand increases as trimester increases. During first and 
second trimester it is about 30-40mg (3-4mg is absorbed) and third 
trimester it is about 60-70mg (6-7mg is absorbed). Total4 iron 
requirement during pregnancy is about 1000mg. 
o fetus and placenta-300 mg 
o maternal haemoglobin-500mg   
o excretion-200 mg 
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IR0N ABSORPTION: 
Iron is absorbed in the upper part of duodenum. 
 Only ferrous form of iron is absorbed not the ferric form. 
 Ascorbic acid, gastric Hcl, cysteine & SH group of protein 
favour iron absorption by reducing ferric to ferrous form. 
 50-60 mg of ascorbic acid is sufficient for normal absorption. 
 Calcium, copper, lead, phosphates and phytates inhibit iron 
absorption by forming insoluble iron salts. 
 In iron deficiency anaemia iron absorption is increased 10 times 
 Iron absorption is  also regulated by hepcidin  a protein 
synthesized by liver in response to intrahepatic iron stores 
 
TRANSPORT: 
 Iron in ferrous form is oxidized to ferric form in mucosal cells 
 It combines with Apo ferritin and forms ferritin. 
 From the mucosal cells it enters the plasma in ferrous form 
 It is oxidized to ferric form by ferroxidase. 
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 Ferric iron binds with the specific iron binding protein 
transferrin or siderophilin 
 Transferrin is the major transport form of iron. 
 Normal range of transferrin-250-450milligram/dl 
 One molecule transports 2 ferric atoms and its half-life-7-10 
days 
 Total iron binding capacity of transferrin-250-450 µg/dl 
 In iron deficiency anaemia TIBC is increased 
 
STORAGE: 
 Iron is stored in liver, spleen, bone marrow in the form of 
ferritin. 
 Ferritin is the index of iron stores. 
 It contains 23% of iron. 
 Ferritin is also an acute phase reactant elevated in inflammatory 
condition. 
 Normal range -15-150 ng/ml. 
  In iron deficiency anaemia serum ferritin is decreased. 
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 Disorder of iron metabolism results in defective erythropoiesis 
leading to iron deficiency anaemia. 
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IRON DEFICIENCY ANAEMIA: 
 Defined by world health organisation as hemoglobin less 
than 11gm in postnatal women. Iron deficiency is the first common 
cause of anaemia in postpartum women, second is due to acute blood 
loss during delivery. Each ml of blood loss result in loss of 0.5mg 
iron. Prevalence in India varies from 50-70%. About 20% of maternal 
deaths worldwide is attributed to anaemia. In India 36% of maternal 
death is because of anaemia. 
 In healthy women with iron supplementation during 
pregnancy prevalence of anaemia in postpartum is about 14%.So 
without iron prophylaxis postpartum anaemia increased to about 
24%.  
 
PREVALENCE: 
 Different1 regions of world are classified by WHO into 
different categories depending on the prevalence of anaemia. 
o High prevalence - >40% 
o Medium prevalence - 15-39% 
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o Low prevalence -      5-14.9% 
o Not a problem -   <5% 
 Currently Center for Disease control and Prevention (CDC; 
Atlanta, Georgia) recommends selective anaemia screening at 4-6 
weeks postpartum for women who had anaemia continued through 
the third trimester, excessive blood loss during delivery, and multiple 
births. 
 
HIGH RISKS GROUP: 
 Uncorrected anaemia during antenatal period 
 Teenage pregnancy 
 Low socio economic status 
 Multiple births without adequate spacing 
 Multiple pregnancy 
 Chronic liver disease 
 Chronic kidney disease due to decreased erythropoietin 
 Hemolytic disorder 
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CAUSES: 
 Increased blood loss during delivery (In normal vaginal 
delivery >500ml, caesarean>1000 ml) 
 Iron malabsorption due to vomiting, or due to 
gastrointestinal disease 
 Due to intake of iron deficient foods. 
 Due to hookworm infestations 
 
STAGES OF IRON DEFICIENCY ANAEMIA: 
There2 are three stages of development of iron deficiency anaemia. 
1. storage iron depletion 
2. Iron deficient erythropoiesis 
3. Iron deficiency anaemia. 
 
STAGE IF STORAGE IRON DEPLETION: 
  Status of iron stores assessed by measuring the 
concentration of serum ferritin. Ferritin is a polypeptide of molecular 
weight 450000 kDa.. 1ng/ml of serum ferritin is equivalent to 8mg of 
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storage iron. Normal range 15-150 ng/ml levels less than 12 ng indicates 
complete depletion of iron stores. Low ferritin is a sensitive marker of 
iron deficiency but it is not very specific as it is an acute phase reactant 
elevated in infection and inflammation. Storage iron depletion leads to 
early functional iron deficiency which signifies that the iron supply to 
the bone marrow and the other tissue is marginally inadequate but there 
is still no anaemia. 
 
CATEGORIES OF IRON DEFICIENCY: 
 
 
STAGE OF IRON DEFICIENT ERYTHROPOIESIS: 
 It is diagnosed by ferro kinetic studies a battery of tests that 
diagnose and differentiate it from other anaemic conditions. In this stage 
the peripheral smear shows normocytic cells. Laboratory test used to 
Degree of iron deficiency Haemoglobin Serum ferritin 
Iron deficient not anaemic >11gm/dl <12ng/ml 
Iron deficiency anaemia <11gm/dl <12ng/ml 
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detect this stage are serum transferrin saturation (percentage), total iron 
binding capacity (TIBC), erythrocyte zinc protoporphyrin concentration 
(ZPP), soluble transferrin receptor concentration assay. Transferrin 
saturation is calculated from the ratio of serum iron to TIBC. Free 
erythrocyte protoporphyrin represents the substrate for heme synthesis. 
Levels rise when there is defective iron supply for the developing red 
cell. Mild form of IDE is associated with ZPP-ratios between 40 and 70 
µ mol/mol. Advanced IDE is associated with >70 µ mol/mol. 
 Serum iron transferrin receptor (Tfr) measured by ELISA is 
a reliable method for assessing cellular iron status. It is particularly 
valuable in identifying iron deficiency in pregnancy since it is the only 
measurement to accurately reflect the iron deficit between the points of 
storage iron depletion and development of anaemia. Serum Tfr increases 
progressively in direct proportion to the magnitude of iron deficiency. 
Iron deficiency is associated with 3-5 fold increase in the concentration 
of these receptors. 
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PARAMETERS NORMAL 
RANGE 
IDA 
Serum iron 
µg/dl 
60-120 <60 
Serum ferritin 
ng/ml 
15-150 <15 
TIBC µg/dl 325-400 >400 
Transferrin saturation 20-50% <15% 
Tfr mg/dl 5.8 8.8 
ZPP µg/dl <40 >70 
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STAGE OF IRON DEFICIENCY ANAEMIA: 
  It represents the tip of iceberg. Changes in the red cell 
indices is the good indicator of iron deficiency. Mean cell volume 
(MCV), Mean cell haemoglobin (MCH), and mean cell haemoglobin 
concentration are all reduced. There is also decreased packed cell 
volume. The peripheral smear picture is typically microcytic 
hypochromic. New cells are being generated at the normal rate and the 
reticulocyte shows little deviation from the normal and it is increased. 
The cells besides being smaller than normal, they are of unequal size and 
abnormal staining i.e. anisocytosis and polychromasia. 
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   MICROCYTIC                   HYOCHROMIC                       PICTURE 
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HEMATOLOGICAL PARAMETERS IN DIFFERENT TYPES OF 
ANAEMIA: 
 
  
 
 
 
TYPE OF 
ANAEMIA 
PCV MCV MCH MCHC RBC MASS 
Normocytic Decreased Normal or 
increased 
Normal Normal Decreased 
Microcytic 
hypochromic 
Decreased Decreased Decreased Decreased Normal or 
decreased 
macrocytic Decreased Increased Increased Decreased Normal or 
decreased 
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GRADES OF ANAEMIA: 
 
 
SIGNS AND SYMPTOMS: 
 Postpartum women with iron deficiency anaemia have poor 
quality of life. They require longer hospitalisation. In mild anaemia they 
may be asymptomatic. Mostly they have, 
 Easy fatigability 
 breathlessness  
 palpitation 
 Decreased lactation 
 Postnatal depression  
CATEGORY HAEMOGLOBIN LEVEL(g/dl) 
Mild 8.0-10.9 
Moderate 5.0-7.9 
Severe Less than 5 
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They develop complications like,  
 Subinvolution of uterus 
 puerperal sepsis 
 Deep vein thrombosis 
 Cardiac failure in severe anaemia 
 Cortical vein thrombosis 
 They have signs like facial pallor, koilonychia, and 
tachycardia, haemic (systolic) murmur due to increased haemodynamic 
circulation, facial puffiness and pedal edema. JVP is increased in cardiac 
failure. 
 
DIAGNOSIS: 
 The Traditional method to diagnose anaemia is by 
hemoglobin estimation and by doing peripheral smear. Other parameters 
used are the packed cell volume, blood indices like MCV, MCH, MCHC, 
serum ferritin, serum iron, TIBC, Transferrin saturation. 
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PREVENTION: 
 Iron deficiency anaemia can be prevented by oral iron 
prophylaxis. So in order to prevent anaemia in antenatal and postnatal 
period2 WHO  recommends 60mg of elemental iron with 400 microgram 
of folic acid per day  for 6 months prophylactically where the prevalence 
of anaemia in pregnancy is <40%.This dose is supplemented for another 
3 months postpartum if the prevalence is > 40%. 
 In India where anaemia affects all age group, women are 
already deficient in iron store,so when they enter into pregnancy and 
puerperium where the iron demand is very high they are more prone to 
develop iron deficiency anaemia.So the National Nutritional anaemia 
control  programme of  India  recommends 100mg of elemental  iron plus 
500 microgram of folic acid prophylactically for 100 days starting from 
the second trimester. 
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MANAGEMENT: 
 Iron deficiency anaemia is managed by oral iron, 
intramuscular iron, intravenous iron, and blood transfusion depending on 
the severity of anaemia. Oral iron has poor compliance of the patients, 
gastrointestinal side effects. Intramuscular iron is painful. They may 
develop anaphylactic reactions, arthralgia, dizziness, fever, headache, 
malaise, fever, headache and vomiting. They require test dose. 
 Intravenous iron-First generation is the iron dextran which 
require test dose and longer duration for administration and have side 
effects. The only advantage is possibility of giving large dose around 
1000mg in single sitting. 
 Second generation is the Iron sucrose where test dose is not 
required and with fewer side effects. No severe anaphylactic reactions 
reported so far. Third generation intravenous iron is the ferric 
carboxymaltose, ferumoxytol, iron isomaltoside. Ferric carboxymaltose 
is approved by FDA and is upcoming in the management of iron 
deficiency in postpartum and in pregnancy as well in second and third 
trimester. 
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 The response to iron therapy is monitored by improvement 
of symptoms and by the reticulocyte count. The absence of response 
warrants complete investigations, including bone marrow biopsy. 
 According to the 10th five-year plan (ICMR) oral iron in 
therapeutic dose should be administered in mild anaemia. However in 
moderate to severe anaemia second and third generation iron should be 
started as first line therapy irrespective of blood transfusion because of 
increased transfusion reactions and transfusion associated infections like 
HIV,Hepatitis B ,Hepatitis C,cytomegalovirus etc.   Parenteral iron has 
several advantages because of less allergic reactions and fewer side 
effects. Parenteral iron has a high availability for erythropoiesis, little 
renal excretion and low tissue accumulation and toxicity 
 SETU RATHOD5 et al conducted a study in SCB Medical 
college,Cuttack, between September 2010 and august 2012.The study 
included 366 women with postpartum anaemia  with haemoglobin 
<10gm/dl and were randomly assigned to receive oral iron or iron 
sucrose or FCM. Changes in haemoglobin and serum ferritin at 2week 
and 6 week after treatment were measured and analysed using 
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ANNOVA. A statistically significant increase in Hb and serum ferritin 
were observed in all three groups but the increase in FCM group was 
significantly higher  (p<0.00001) than conventional iron sucrose and oral 
iron group. The mean increase in Hb after 2nd week was 
0.8;2.4;3.2gm/dl and 2.1;3.4 and 4.4 gm/dl at 6 weeks. The mean 
increase in serum ferritin after 2 weeks was 2.5;193.1;307.1 and 
14.2;64;106.7ng/ml, after oral iron, iron sucrose and   FCM groups 
respectively. Adverse drug reactions were significantly less (p<0.001) in 
FCM group when compared with other two groups. They concluded that 
FCM elevates Hb level and serum ferritin level faster than iv iron sucrose 
and oral iron.This study was published in International journal of applied 
and basic medical researchJan-april 2015,Vol 5,Issue 1. 
 DAVID B.VAN WYCK6 et al conducted a randomized 
multicenter trial in 43 centers; 40 in United States, 3 in Mexico. They 
selected anaemic women with Hb equal to or less than 10gm within 10 
days postpartum .174 patients received 350 iron doses of FCM (mean 
total dose 1403.1mg) in 3,2 or 1 injection (10.9%,79.3%,9.8% of patients 
respectively).178 received oral iron. Patients who received FCM 
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achieved Hb rise equal to or greater than 2 gm/dl earlier (7.0 days 
compared with 14 days p<0.001), were more likely to achieve a Hb rise 
greater than or equal to 3.0 gm /dl at any time (86.3% compared with 
60.4%, p<0.001) and were more likely to achieve a Hb greater than 12 
gm/dl (90.5% compared with 68.6%, p<0.001) when compared with oral 
iron. 
 CHRISTIAN BREYMANN7 et al (International journal of 
Gynaecology and Obstetrics 2008) compared the efficacy of iron 
carboxymaltose with ferrous sulphate to treat iron deficiency anaemia in 
postpartum. Patients were randomized (2:1 ratio) to receive FCM 9upto 
3 weekly doses of 1000mg maximum, applied in 15 minutes ( n=227) or 
ferrous sulphate (100mg twice daily,12 weeks, n=117). Changes in Hb 
and iron stores upto 12 week analyzed. They concluded that parenteral 
FCM is a safe and effective treatment for postpartum anaemia with 
advantages of a shorter treatment period, better compliance, rapid return 
of iron stores and lower side effects. 
 MELVIN H SEID8 et al, conducted a multicenter 
randomized trial at 28 centers in united states between May 9,2006 and 
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Dec 27,2006(AJOG 2008).291 women less than 10 days after delivery 
with haemoglobin 10gm /dl or less were randomized to receive the FCM 
(n=143),1000 mg or less intravenously over 15 minutes or less, 
repeatedly weekly to a calculated replacement dose (maximum 2500mg) 
or ferrous sulphate (n=148) 325mg orally thrice daily for 6 weeks. FCM 
patients achieved 1) a haemoglobin greater than 12g/dl in shorter time 
period with shorter time period with sustained haemoglobin greater than 
12 g/dl at day 42.2) achieve Hb rise 3g/dl or greater more quickly. 
3)attain higher serum transferrin saturation and ferritin levels.  
 Patel10 et al conducted a clinical observational study at 
tertiary care teaching hospital (SBKS Medical Institute and Research 
Centre) for a period of 4 months in 30 pregnant and 30 post-partum 
women. The baseline hemoglobin and serum ferritin levels were 
recorded prior to treatment. After completion of the treatment the women 
were followed up for changes in hemoglobin and serum ferritin levels on 
day 8 and day 15. The mean rise of hemoglobin value was 5.2gm/l for 
ferric carboxymaltose and 4.1gm/l for iron sucrose in pregnant women. 
For postpartum women mean rise of hemoglobin was 4.9gm/l on the 15th 
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day of treatment. Side effects were reported in 40% among patients 
treated with iron sucrose as compared to 16.67% in case of ferric 
carboxymaltose. Ferric carboxymaltose administration in pregnant 
women is safe and well tolerated by postpartum women. Ferric 
carboxymaltose is associated with fewer side effects as compared to iron 
sucrose in present study. It also offers the advantage of a much higher 
iron dosage at a time reducing the need for repeated applications and 
increasing patients comfort. 
 Lysung -Williamson KA12 et al reviewed many trials, patient 
received FCM equivalent to an iron dose of less than or equal to 1000 
mg (or 15 mg/kg in those weighing <66 kg) administered over less than 
or equal to 15 minutes or 100 mg of iron twice daily in postpartum 
patients. FCM improves haemoglobin level and replenish depleted iron 
stores and improve health related quality of life in patients with iron 
deficiency anemia.  
 Bernd Froessler14 et al conducted prospective observational 
study with 65 anaemic pregnant women who received ferric 
caroxymaltose upto 15mg/kg between 24 and 40 weeks of pregnancy. 
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The study showed significant increase in Hemoglobin values above 
baseline levels in all women. Ferritin levels increased significantly after 
the infusion. 
 Khalafallah11 et al did a prospective randomized controlled 
study at two centers in Tasmania, Australia, in patients undergoing 
elective surgery with IDA. Between Dec 2014 and May 2015, 201 
eligible patients are recruited. 103 were assigned to intravenous FCM 
and 98 to standard care. Baseline haemoglobin was 105.5g/L (SD 13.8) 
in the standard group versus 106.2g/L(11.9) in the FCM ,improving at 4 
weeks to 121.5g/L(SD 14.5) in the standard group and 130.1g/L (11.3) 
in the FCM group(mean difference of 7.8g/L,95%CI 3.79-11.9;p<0.0001 
in favour of FCM group). Significant improvements in serum iron 
(5.36micromol/L,95%CI 3.62-7.09;P<0.0001),iron saturation 
(11.4%,95% CI 8.33-14.50;P<0.0001) and serum ferritin saturation (468 
microgram /L,95% CI 355-582;P<0.0001) were also noted in FCM 
group at 4 weeks compared with standard care, although no differences 
were noted in transferrin concentrations(0.06 g/L,95% CI0.01-
0.85;P=0.O35). No adverse reactions with FCM noted. Postoperative 
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intravenous FCM is a feasible and pragmatic management approach in 
surgical patients with functional IDA. 
 Rognoni.C13 et al performed a systematic literature review 
of published RCTs on the use of FCM in iron deficiency between July 
and October 2014. The initial search yielded 1027 citations, which was 
decreased to 21 studies eligible for inclusion in the review. Studies were 
heterogeneous in the number of patients randomised, iron deficiency-
related conditions addressed, trial inclusion criteria, time horizon, 
treatment dosage and outcomes assessed. Six studies with the same time 
horizon (i.e. 6 weeks) were included in the network meta-analysis. 
Considering the differences between final and initial outcome values for 
each iron formulation, the mean difference of these differences (delta) 
was estimated for each couple of treatments involving ferric 
carboxymaltose. Significant improvements in serum ferritin (µg/l) were 
obtained with ferric carboxymaltose compared to oral iron (delta 172.8; 
95 % CI 66.7–234.4) and in haemoglobin (g/dl) with respect to ferric 
gluconate (delta 0.6; 95 % CI 0.2–0.9), oral iron (delta 0.8; 95 % CI 0.6–
0.9) and placebo (delta 2.1; 95 % CI 1.2–3.0). 
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 Kuster M15 et al retrospectively analyzed data from 173 
patients Intravenous ferric carboxymaltose led to a significant increase 
in hemoglobin and serum ferritin levels. Side effects of intravenous 
treatment were found in 2% of all case. 
 Mahey R16 eta al conducted randomized control trial 
between April 2013 and May 2014 in patients older than 18yrs of age 
presenting in a hospital in New Delhi with anemia due to abnormal 
uterine bleeding. One group received iron sucrose and other one received 
FCM. Increase in mean Hb from baseline is higher in FCM group at 6 
weeks. P =.005. Treatment with FCM resulted in rapid increase in 
hemoglobin level in patents with anemia due to abnormal uterine 
bleeding. 
 Breymann C17 compared the efficacy and safety of 
intravenous FCM with first line ferrous sulphate in pregnant women with 
iron deficiency anaemia. Pregnant women (n=252), with mean 
gestational age 16-33 weeks with iron deficiency anaemia were 
randomized 1:1 to FCM (1000-1500mg) or Ferrous sulphate(200mg of 
Fe/day) for 12 weeks. Significant women achieved anaemia correction 
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with FCM Vs Ferrous sulphate. (Hb ≥11gm/dl, 84% vs 70%; odds ratio 
2.06; 95% confidence interval.1.07,3.97; p=.031) with in shorter time 
(3.4 Vs 4.3 weeks). FCM significantly improved vitality (p=0.025) and 
social functioning (p=0.049) prior to delivery. Adverse reactions were 
low with FCM when compared with ferrous sulphate. 
 Christoph P19 performed a retrospective analysis of 206 
pregnant women treated with either ferric carboxymaltose or iron 
sucrose for iron deficiency anaemia with intolerability to oral iron 
substitution or insufficient haemoglobin increase after oral iron 
treatment or need for rapid haemoglobin correction. The mean rise in 
haemoglobin was significantly higher in women who received FCM. The 
rise in haemoglobin was 15.4g/dl for FCM and 11.7 g/dl for iron sucrose. 
 ONKEN JE18 evaluated FCM vs oral iron in iron deficiency 
anaemia patients. After 14 days of oral iron, 507 participants responding 
inadequately to oral iron (haemoglobin <10g/dl were assigned to group 
A (2 doses of FCM 750mg 1 week apart) or Group B (oral iron 325 mg 
thrice /day for 14 additional days. Another 504 participants who were 
not appropriate for oral iron were assigned as Group C to receive FCM 
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as above or Group D (standard care). Mean increase in Hb was 
significantly greater in Group A-FCM than Group B oral iron 1.57( 
±1.19)g/dl versus 0.80(±0.80)g/dl(p=0.001). Comparison of Group C vs 
Group D also demonstrated significant mean increase in Hb from 
baseline to highest value.2.9(±1.64)g/dl versus 
2.16(±1.25)g/dl(p=0.001) 
 Dillion R20 et al from a retrospective single center study 
compared the efficacy of three intravenous iron preparations (iron 
dextran, iron sucrose, and FCM) in 280 patients. While comparing the 
haemoglobin and other measures of Iron deficiency, after six weeks of 
treatement, they have showed statistically and clinically significant 
increase in haemoglobin level with FCM group. 
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IRON SUCROSE: 
CHEMICAL FORMULA: 
 C₁₈H₂₄Fe₂O₂₄ 
 
 Iron sucrose is a brown, sterile, aqueous complex of 
polynuclear iron (III) hydroxide in sucrose containing 20mg of elemental 
iron per ml. 
 The sterile solution has an osmolality of 1250mosm/l. the 
product does not contain preservatives. 
 Molecular wt: 34,000-60000 daltons. 
 pH:10.5 -11.1 
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MECHANISM OF ACTION: 
 Following intravenous administration, it is dissociated into 
iron and sucrose by reticuloendothelial system and iron is transferred 
from the blood into pool of iron in the liver and bone marrow. Ferritin 
sequesters iron in a nonionic form from which iron is easily available. 
Iron is transported as a complex with transferrin to target cells including 
erythroid precursor cells. The iron in the precursor cells is incorporated 
into haemoglobin as the cells mature into red blood cell. 
 
PHARMACOKINETICS: 
 Its iron component exhibits first order kinetics. 
Half-life: 6 hrs 
Total clearance: 1.2 litres/hour 
Non-steady state apparent volume of distribution : 10 litres 
Steady state apparent volume of distribution: 7.9 litres. 
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DISTRIBUTION: 
 In healthy adults, its iron component appears to distribute 
mainly in blood and to some extent in extra cellular fluid. 
 
ELIMINATION: 
  The sucrose component is eliminated mainly by urinary 
excretion. Some iron is also eliminated in the urine (approximately 5%) 
within 24 hrs. 
 
SIDE EFFECTS: 
 Head ache, fever, pain, asthenia, malaise, abdominal pain. 
 
INTERACTION: 
 Should not be administered concomitantly with oral iron 
preparation since the absorption of oral iron may be reduced. 
 Chloramphenical may decrease the effect of iron sucrose 
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CONTRA INDICATIONS: 
 1. Evidence of iron over load. 
 2. Anemia not caused by iron deficiency. 
 3. Known hypersensitivity to I.V iron sucrose (or) any of its 
inactive compounds. 
 
METHODS AND ROUTE OF ADMINISTRATION: 
 No test dose is required. 
1. Slow IV injection: 
 100mg (2 amp) to be given undiluted over a period of 2 – 5 
minutes.  
2. Slow IV infusion: 
 100mg (2amp) to be diluted with 100ml of normal saline 
immediately prior to infusion and to be infused over a period of atleast 
15min(6mg/min). 
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DOSAGE FREQUENCY: 
 200mg/day given on alternate days until the required dose is 
infused. 
 Chandler et al observed that optimal doses of 200-300mg 
infused intravenously over 2 hours were well tolerated and safe. Patients 
who received a dose of 400-500mg intravenously over 2 hours 
experienced hypotension, nausea and low back pain. 
 
SUPPLY AND STORAGE: 
 Supplied as 5 ml single dose vial. Each 5 ml vial contains 
100mg of elemental iron (20mg/ml). Stored at 25°C. Excursions 
permitted to 15-30°C. 
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IRON SUCROSE INJECTION : 
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FERRIC CARBOXYMALTOSE: 
 Parenteral iron complex consisting of colloidal ferric III 
hydroxide core stabilized by carbohydrate shell so there is controlled 
delivery of iron to cells of reticuloendothelial system and subsequent 
delivery to the iron binding proteins ferritin and transferrin .It has low 
immunogenic potential, dextran free product and not predisposed to 
anaphylactic reaction. 
 
MECHANISM OF ACTION: 
 FCM results in transient elevations in serum iron, serum 
ferritin and transferrin saturation and ultimately the correction of 
haemoglobin and replenishment of depleted iron stores.serum iron 
concentrations increase in dose dependent manner after intravenous 
FCM. 
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CHEMICAL FORMULA:  
 [FeOx(OH)y(H2₂O)z]n [{C₆H₁₀O₅)m(C₆H₁₂O₇)}l]k 
n=10³; m=8; l=11; k=4 (l-represents the mean branching degree of the 
ligand) 
 
 
  
Half-life :4-12 hours. 
pH:5-7 (neutral)  
Molecular weight: 150000 daltons 
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DISTRIBUTION: 
 FCM is cleared rapidly from the circulation and distributed 
mainly in the bone marrow (approximately 80%) and also to the spleen 
and bone marrow. 
 
FCM INJECTION : 
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INDICATIONS: 
 iron deficiency anemia 
 pregnancy 
 postpartum 
 Anemia due to chronic kidney disease 
 Anemia in abnormal uterine bleeding. 
 Anaemia in inflammatory bowel disease 
 
CONTRAINDICATIONS: 
 Hypersensitivity to iron products. 
 Iron overload 
 
METHOD AND ROUTE OF ADMINISTRATION: 
 Slow intravenous infusion-Maximum of 1000 
mg/week/dose diluted in 0.9 normal saline and infused over 15 minutes. 
STORAGE:  
 Do not store above 30°C. Do not freeze 
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SHELF LIFE:  
 36 months.  
 
EXCIPIENTS:  
 Sodium hydroxide and hydrochloric acid for PH adjustment 
 
SIDE EFFECTS: 
 Headache, dizziness, nausea, abdominal pain, constipation, 
diarrhoea, and injection site reactions. 
 
MONITORING PARAMETERS: 
 During transfusion the patient should be continuously 
monitored by blood pressure, pulse rate and for any adverse reactions. 
They should be monitored for 30-60 minutes following infusion for 
transfusion reactions. 
 
 
 
MATERIALS AND 
METHODS 
  
45 
 
MATERIALS AND METHODS 
 The study was conducted in Govt RSRM Lying Hospital -
Stanley Medical College, Chennai during year August 2015 – 2016. 
 100 Postnatal women with hemoglobin between 8-10gm% 
were selected and placed randomly into two groups. One group of 50 
postnatal mother received iron sucrose while the other 50 postnatal 
mother received Ferric carboxymaltose. 
 
INCLUSION CRITERIA: 
 Postnatal women with Iron deficiency anaemia with HB 8-
10gm. 
 
EXCLUSION CRITERIA: 
 H/O Allergy to iron compound 
 Chronic kidney disease 
 Anaemia due to other causes(Including postpartum 
Haemorrhage) 
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 Hematological disorder 
 Bronchial asthma 
 Hepatitis 
 HIV 
 Heart disease 
 H/O recent blood transfusion 
 
DOSE CALCULATION: 
 In postnatal women 24 hrs after delivery Haemoglobin 
estimation, blood indices, peripheral smear and serum ferritin should be 
done. Patient with iron deficiency anaemia with HB between 8 to 10gm 
were selected. Required iron dose is calculated using the formula below. 
Target HB is 12 gm. 
  
2.4 x Body weight in Kg x (Target HB - Actual HB) +500 gm. 
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IRON SUCROSE: (No test dose is required) 
1. It is given by IV injection according to the iron dose calculated and 
rounded up to the nearest multiple of 100 for each individual.  
2. 200 mg elemental iron diluted in 200 ml 0.9% normal Saline is the 
maximum dose given over 15 to 20 min and repeated on alternate 
days as required. 
FERRIC CARBOXYMALTOSE: (No test dose is required) 
1) It is given by IV injection according to the iron dose calculated and 
rounded up to the nearest multiple of 100 for each individual. 
2) Maximum single dose of 1000 mg diluted in 250 ml of 0.9% 
normal Saline given over 15 minutes and not more than once a 
week. 
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DATA ANALYSIS AND INTERPRETATION: 
 Data analysis is a systematic organization and synthesis 
of research data and testing of research hypothesis using that data. 
Interpretation is the process of making sense of the study and 
examining the implication (Polite and Beck, 2004). In this study the 
data was collected, assembled, analyzed, tested individually. 
Paired’t’ test:  
 This test was adopted to determine the effect of iron sucrose 
and FCM before, 2 weeks and 4 weeks after therapy.  
Independent t test: 
  This test is used to identify whether there is significant 
difference among iron sucrose and FCM group.  
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INVESTIGATIONS: 
 Hemoglobin,  
 Peripheral smear,  
 Mean Corpuscular Volume,  
 Serum Ferritin 
Pre-treatment and 2nd and 4th week post-treatment investigations are done 
for both the groups and results are compared. 
 
MONITORING PARAMETERS: 
 Blood pressure 
 Pulse rate 
 Temperature 
 Allergic reactions 
 Nausea 
 Vomiting 
 
 
 OBSERVATION AND 
RESULTS 
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OBSERVATION AND RESULTS 
IRON SUCROSE: 
 Following are the demography features of Iron Sucrose 
participants and their outcomes following Iron Sucrose administration. 
 
AGE DEMOGRAPHY IN IRON SUCROSE: 
 Out of 50 women studied in  iron sucrose group 30%(n=15) 
belong to age group 15-20yrs,44% belong to age group 21-
25yrs(n=22),24% belong to 26-30 yrs(n=12),2% belong to 31-35 
yrs(n=1).  
 
AGE Count Percentage 
age 15-20 15 30% 
age 21-25 22 44% 
age 26-30 12 24% 
age 31-35 1 2% 
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PARITY IN IRON SUCROSE: 
 Among parity distributon 52% belong to P2L2,36% belong 
to P1L1 ,8% belong to P3L3 and 4% belong to P4L4 group.so prevalence 
of anaemia is more among multiparas. 
 
OB.Code Parity Count Percentage 
1 P1L1 18 36% 
2 P2L2 26 52% 
3 P3L3 4 8% 
4 P4L4 2 4% 
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MODE OF DELIVERY (MOD) IN IRON SUCROSE: 
 Among mode of deliveries 31 deliveries were labour natural 
(includes with episotomy and with lacerated perineum), forceps delivery 
-2 and emergency lscs- 17(includes repeat lscs and repeat lscs with 
sterilization) 
 
MOD.Code MOD Iron sucrose 
1 Labour Natural 11 
2 Labour Natural with Episotomy 17 
3 Labour Natural with LP 3 
4 FORCEPS 2 
5 Emergency LSCS 8 
6 Emergency Repeat LSCS 3 
7 Emergency Repeat LSCS ST 6 
8 VBAC 0 
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MEAN HEMOGLOBIN TREND IN IRON SUCROSE GROUP: 
 Improvement of haemoglobin with iron sucrose from 
pretreatment haemoglobin ( mean) 8.57 gm to 10.22(mean) at two weeks 
and to 10.92(mean) at 4 weeks. The average increase is about 1.65 gm at 
2 weeks and 2.35gm at 4 weeks. 
 
Iron Sucrose Pre Hb Hb 2weeks Hb 4 weeks 
Pre Hb 8.57   
Hb 2weeks  10.22  
Hb 4weeks   10.92 
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MEAN MCV TREND IN IRON SUCROSE GROUP: 
  There is also significant increase in the MCV 
following iron sucrose treatment. Pretreatment MCV is about 
80.12(mean value) and 84.22(mean) at two weeks and 85.449(mean) at 
4 weeks.  
 
Iron Sucrose Pre MCV MCV 2weeks MCV 4 weeks 
Pre MCV 80.12   
MCV 2weeks  84.22  
MCV 4weeks   85.44 
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MEAN SERUM FERRITIN TREND IN IRON SUCROSE 
GROUP: 
 Serum ferritin increases from average of 37.12 
ng/ml to 119.97 ng/ml at two weeks and there is a fall at four weeks 
113.62ng/ml following redistribution of iron. 
 
Iron Sucrose 
Pre 
Sr.Ferritin 
Sr.Ferritin 
2weeks 
Sr.Ferritin 4 
weeks 
Pre Sr.Ferritin 37.12   
Sr.Ferritin 2weeks  119.97  
Sr.Ferritin 4weeks   113.62 
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SIDE EFFECTS: 
 Among iron sucrose group, 7 persons reported  side effects. 
Among side effects: 
 4 reported nausea with or without vomiting  
 2 reported giddiness 
 1 reported urticarial 
0
20
40
60
80
100
120
Pre Sr.Ferritin Sr.Ferritin 2weeks Sr.Ferritin 4weeks
37.12
119.97
113.62
S
r.
F
e
rr
it
in
 i
n
 n
g
SERUM FERRITIN TREND-IRON SUCROSE GROUP
Pre Sr.Ferritin
Sr.Ferritin 2weeks
Sr.Ferritin 4 weeks
61 
 
 
Total pts  side effects reported Percentage 
50 7 14% 
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FERRIC CARBOXYMALTOSE (FCM): 
 Following are the demography features of Ferric 
Carboxymaltose participants and their outcomes following FCM 
infusion. 
 
AGE DEMOGRAPHY IN FCM GROUP: 
  Out of 50 women studied in FCM group 28%(n=14) belong 
to age group 15-20yrs, 46% belong to age group 21-25yrs(n=23), 22% 
belong to 26-30 yrs(n=11), 2% belong to 31-35 yrs(n=1).  
AGE Count Percentage 
age 15-20 14 28% 
age 21-25 23 46% 
age 26-30 11 22% 
age 31-35 2 4% 
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PARITY IN FCM GROUP: 
 Among parity distributon 44% belong to P2L2, 42% belong 
to P1L1, 12% belong to P3L3 and 2% belong to P4L4 group. So 
prevalence of anaemia is more among multiparas 
OB.Code Parity FCM Percentage 
1 P1L1 17 42% 
2 P2L2 26 44% 
3 P3L3 6 12% 
4 P4L4 1 2% 
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MODE OF DELIVERY (MOD) IN FCM GROUP: 
  Among mode of deliveries 30 deliveries were labour natural 
(includes with episotomy and with lacerated perineum), forceps delivery 
-1 and emergency lscs- 18(includes repeat lscs and repeat lscs with 
sterilization) and VBAC 1. 
 
MOD.Code MOD FCM 
1 Labour Natural 10 
2 Labour Natural with Episotomy 17 
3 Labour Natural with LP 3 
4 FORCEPS 1 
5 Emergency LSCS 8 
6 Emergency Repeat LSCS 4 
7 Emergency Repeat LSCS ST 6 
8 VBAC 1 
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SOCIO ECONOMIC STATUS: 
 The incidence of iron deficiency anaemia is more among 
low socio economic group for both Iron sucrose and FCM recipients. 
76% belong to class V and 20% belong to IV. 
 
SOCIO ECONOMIC 
CLASS  Count Percentage 
CLASS I _ _ 
CLASS II _ _ 
CLASS III 2 4% 
CLASS IV 10 20% 
CLASS V 38 76% 
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MEAN HEMOGLOBIN TREND IN FCM GROUP: 
  Improvement of haemoglobin with iron sucrose from 
pretreatment haemoglobin ( mean) 8.54 gm to 10.58(mean) at two weeks 
and to 11.37 (mean) at 4 weeks. The average increase is about 2.04 gm 
at 2 weeks and 2.83gm at 4 weeks. 
 
 
FCM Pre Hb Hb 2weeks Hb 4weeks 
Pre hb 8.54   
Hb 2weeks  10.58  
Hb 4weeks   11.37 
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MEAN MCV TREND IN FCM GROUP:  
 There is also significant increase in the MCV 
following iron sucrose treatment. Pretreatment MCV is about 
78.94(mean value) and 86.28 (mean) at two weeks and 88.18(mean) at 
4 weeks. 
FCM Pre MCV MCV 2weeks MCV 4 weeks 
Pre MCV 78.94   
MCV 2weeks  86.28  
MCV 4weeks   88.18 
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MEAN SERUM FERRITIN TREND IN FCM GROUP:  
 Serum ferritin increases from average of 31.5 
ng/ml to 266.02 ng/ml at two weeks and there is a fall at four weeks 
130.86 ng/ml following redistribution of iron 
 
FCM 
Pre 
Sr.Ferritin 
Sr.Ferritin 
2weeks 
Sr.Ferritin 4 
weeks 
Pre Sr.Ferritin 31.5   
Sr.Ferritin 2weeks  266.02  
Sr.Ferritin 4weeks   130.86 
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SIDE EFFECTS:  
 Among FCM group, 3 persons reported  side effects. 
Among side effects: 
 2 reported nausea  
 1 reported arthralgia 
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TOTAL  
SIDE EFFECTS 
NOTED Percentage 
50 3 6% 
 
 
 
Testing of hypotheses: 
 Iron sucrose treatment and Ferric carboxy 
maltose treatment are effective in   increasing HB, MCV and Sr. Ferritin. For 
this I used paired test due to pre and post test scores. 
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Paired’t’ test:  
This test was adopted to determine the effect of iron sucrose and FCM  
before and immediately after the intervention. It was calculated by using the 
formula      
   
nSD
d
t
/

 
 
 SD =  
d= Mean difference of parameters score before and after therapy. 
SD=Standard deviation of individual parameters before and after iron sucrose 
and FCM 
n= Number of sample 
 
Null Hypothesis 1: The Iron sucrose treatment and Ferric carboxymaltose 
treatment are not effective in   increasing HB, MCV and Sr. Ferritin during 
the first two weeks. 
Alternative Hypothesis: The Iron sucrose treatment and Ferric carboxy 
maltose treatment are effective in   increasing HB, MCV and Sr. Ferritin. 
during the first 2 weeks. 
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Level of significance α = .05 
Test Statistic:     
nSD
d
t
/

 
Calculations: 
 
Paired Samples Statistics 
Treatment Code Mean N Std. Deviation Std. Error Mean 
Iron 
Sucrose 
Pair 1 
Pre_Hb 8.572 50 .3933 .0556 
Post2HB 10.22 50 .548 .077 
Pair 2 
Pre_MCV 80.12 50 3.081 .436 
Posrt2MCV 84.22 50 2.332 .330 
Pair 3 
PreSr.Ferritin 37.118 50 9.5262 1.3472 
Post2Sr.Ferritin 199.9716 50 50.92968 7.20255 
FCM 
Pair 1 
Pre_Hb 8.536 50 .4746 .0671 
Post2HB 10.58 50 .448 .063 
Pair 2 
Pre_MCV 78.94 50 4.460 .631 
Posrt2MCV 86.28 50 2.090 .296 
Pair 3 
PreSr.Ferritin 31.504 50 12.6092 1.7832 
Post2Sr.Ferritin 261.0304 50 70.26405 9.93684 
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Paired Samples Test 
TreatmentCode Paired Differences t df Sig. 
(2-
tailed
) 
Mean Std. 
Deviat
ion 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
           
Iron 
Sucros
e 
Pair 
1 
Pre_Hb - 
Post2HB 
-1.6480 .5342 .0756 -1.7998 -1.4962 
-
21.81
3 
49 .000 
Pair 
2 
Pre_MCV - 
Posrt2MCV 
-4.100 2.073 .293 -4.689 -3.511 
-
13.98
8 
49 .000 
Pair 
3 
PreSr.Ferritin 
- 
Post2Sr.Ferriti
n 
-
162.85360 
41.603
0 
5.883
56 
-
174.6770
6 
-
151.0301
4 
-
27.67
9 
49 .000 
FCM 
Pair 
1 
Pre_Hb - 
Post2HB 
-2.0420 .3671 .0519 -2.1463 -1.9377 
-
39.33
8 
49 .000 
Pair 
2 
Pre_MCV - 
Posrt2MCV 
-7.340 3.514 .497 -8.339 -6.341 
-
14.76
8 
49 .000 
Pair 
3 
PreSr.Ferritin - 
Post2Sr.Ferriti
n 
-
229.52640 
58.231
4 
8.235
17 
-
246.0756
0 
-
212.9772
0 
-
27.87
1 
49 .000 
 
Inference:  The p- values for all the combinations are  .000, Since p- values 
are less than the level of significance α=.05, Null hypotheses are rejected and 
Alternative hypotheses are accepted 
78 
 
Conclusion: This shows that the Iron sucrose treatment and Ferric carboxy 
maltose treatment are effective in   increasing HB, MCV and Sr. Ferritin 
during the first two weeks. 
A similar analysis is carried to know whether  the same trend continues 
between the 2nd and the 4th  week of the treatment.  
Null Hypothesis 2: The Iron sucrose treatment and Ferric carboxymaltose 
treatment are not effective in   increasing HB, MCV and Sr. Ferritin during 
the 2nd and the 4th week of the treatment.  
Alternative Hypothesis: The Iron sucrose treatment and Ferric carboxic 
malthouse treatment are effective in   increasing HB, MCV and Sr. Ferritin. 
during the the 2nd and the 4th  week of the treatment.  
Level of significance α = .05 
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Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 
Post2HB 10.40 100 .529 .053 
Post4Hb 11.145 100 .6445 .0645 
Pair 2 
Posrt2MCV 85.25 100 2.434 .243 
Post4MCV 86.81 100 2.286 .229 
Pair 3 
Post2Sr.Ferritin 230.5010 100 68.32905 6.83290 
Post4Sr.Ferritin 122.237 100 2.286 23.4 
 
 
 
 Mean Std. 
Deviati
on 
Std. 
Error 
mean 
t df Sig. (2-
tailed) 
Pair 1 Post2HB - Post4Hb -.7460 .3421 .0342 -21.804 99 .000 
Pair 2 
Posrt2MCV - 
Post4MCV 
-1.560 1.343 .134 
-11.613 99 .000 
Pair 3 
Post2Sr.Ferritin - 
Post4Sr.Ferritin 
108.263
90 
55.1374
4 
5.51374 
19.635 99 .000 
 
Inference:  The p- values for all the combinations are  .000. Since p- values 
are less than the level of significance α=.05, Null hypotheses are rejected and 
Alternative hypotheses are accepted 
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Conclusion: This shows that the Iron sucrose treatment and Ferric carboxy 
maltose treatment are effective in   increasing HB, MCV and Sr. Ferritin 
during the 2nd and the 4th week of the treatment.  
Combining the results of these two tests we conclude that Iron sucrose 
treatment and Ferric carboxymaltose treatment are effective in   increasing 
HB, MCV and Sr. Ferritin. 
 
Independent t test: This test is used to identify whether there is significant 
difference in in Hb, MCV and Sr Ferritin between Iron sucrose treatment 
group and Ferric carboxymaltose treatment group. It is calculated by using 
following methods, 
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x1 = Mean value of Iron sucrose treatment group 
x2 = Mean value of Ferric carboxymaltose treatment group 
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S = Standard deviation of Iron sucrose treatment group and Ferric 
carboxymaltose treatment group 
n1 = Number of samples in Iron sucrose treatment group  
n2 = Number of samples in the Ferric carboxymaltose treatment group  
Null hypothesis: There is no significant difference in Hb, MCV and Sr Ferritin 
between Iron sucrose treatment group and Ferric carboxymaltose treatment 
group. 
Alternative Hypothesis: Ferric carboxymaltose treatment is better than Iron 
sucrose treatment.  
Level of significance α = .05 
Calculations: 
COMPUTE   Increase in HB = Post2Hb - Pre_Hb. 
          Increase in MCV2 = Posrt2MCV - Pre_MCV 
    Increase in changeSr.Fer2 = Post2Sr.Ferritin - Pre Sr.Ferritin 
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Group Statistics 
 
Treatment Code N Mean Std. 
Deviati
on 
Std. 
Error 
Mean 
increase in HB 2weeks 
Iron sucrose 50 
1.648
0 
.53423 .07555 
FCM 50 
2.042
0 
.36706 .05191 
increase in MCV 2weeks 
Iron sucrose 50 
4.100
0 
2.07266 .29312 
FCM 50 
7.340
0 
3.51446 .49702 
 
 
     
increase in Sr Ferritin 2weeks 
Iron sucrose 50 
162.8
536 
41.6030
6 
5.88356 
FCM 50 
229.5
264 
58.2314
6 
8.23517 
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Inference: Since p- values (.000) are less than α ( =.05 ), the null hypotheses 
are rejected consequently alternative hypotheses are accepted. 
Conclusion: Ferric carboxymaltose treatment is better than Iron sucrose 
treatment. The treatments behave over the periods, after 2 weeks and after 4 
weeks. This is done with the help of the technique Mean plot?. 
 
  
 
 
 
 
 
Levene's Test for Equality 
of Variances 
F Sig. t df Sig. (2-
tailed) 
increase in HB 2weeks 
Equal variances 
assumed 
7.416 .008 -4.298 98 .000 
Equal variances 
not assumed 
  
-4.298 86.832 .000 
increase in MCV 
2weeks 
Equal variances 
assumed 
15.519 .000 -5.615 98 .000 
Equal variances 
not assumed 
  
-5.615 79.407 .000 
increase in Sr Ferritin 
2weeks 
Equal variances 
assumed 
14.256 .000 -6.588 98 .000 
Equal variances 
not assumed 
  
-6.588 88.683 .000 
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DOSE REQUIREMENT FOR IRON SUCROSE & FCM: 
 
 IRON SUCROSE FCM 
DOSE 935.53 937.94 
 
 
 
 
 
The mean iron dose required in both iron sucrose and FCM  group is 
about 1000mg. 
 
 
 
 
 
935.53
937.94
934
934.5
935
935.5
936
936.5
937
937.5
938
938.5
Iron Sucrose FCM
DOSE REQUIREMENT FOR IRON SUCROSE & FCM
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COMPARISON OF EFFICACY OF IRON SUCROSE vs FCM 
USING MEAN PLOT: 
COMPARISON OF Hb IN IRON SUCROSE vs FCM: 
 In our study the trend of haemoglobin increase 
in FCM group is faster and greater .the haemoglobin increase is about 
10.92 at 4 weeks in iron sucrose group from baseline value of 8.57g 
where as in FCM group Hb increase is about 11.37 from 8.54. 
 IRON SUCROSE FCM 
PRE Hb 8.57 8.54 
Hb 2weeks 10.22 10.58 
Hb 4week 10.92 11.37 
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COMPARISON OF MCV - IRON SUCROSE Vs FCM: 
 Blood indices also improves following 
intravenous iron formulations. MCV increases about 85.44(fl) from 
baseline of 80.12(fl) in iron sucrose group whereas in FCM it increases 
to about 88.18(fl) from 78.94.so there is significant improvement in 
blood indices following FCM injection…. 
 IRON SUCROSE FCM 
Pre MCV 80.12 78.94 
MCV 2weeks 84.22 86.28 
MCV 4week 85.44 88.18 
0 2 4 6 8 10 12
PRE Hb
Hb 2weeks
Hb 4week
8.57
10.22
10.92
8.54
10.58
11.37
Hb in gms
COMPARISON OF Hb IN IRON SUCROSE Vs FCM
FCM IRON SUCROSE
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COMPARISON OF SR.FERRITIN - IRON SUCROSE Vs FCM: 
 In our study  among iron sucrose group serum 
ferritin increases from baseline (37.2 to 199.98  at 2weeks; 113.61 at 4 
weeks).But the inmprovement is greater among FCM GROUP.(31.5 to 
266.02 at 2 weeks and 130.8 at 4 weeks).the ferritin fall at 4th week is 
due to iron redistribution in haemoglobin formation. 
80.12
84.22
85.44
78.94
86.28
88.18
74
76
78
80
82
84
86
88
90
Pre MCV MCV 2weeks MCV 4week
COMPARISON OF MCV IN IRON SUCROSE Vs FCM GROUP
IRON SUCROSE
FCM
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 IRON SUCROSE FCM 
Pre SR.FERITTIN 37.12 31.5 
SR.FERITTIN 2weeks 199.98 266.02 
SR.FERITTIN  4week 113.6188 130.8 
 
 
 
 
 
37.12
199.98
113.6188
31.5
266.02
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COMPARISON OF SERUM FERRITIN IN IRON SUCROSE Vs FCM GROUP
FCM
IRON SUCROSE
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COMPARISION OF SIDE EFFECTS: 
 Adverse reactions following both groups were 
milder .Following iron sucrose 14%(n=7)  developed side effects like 
nausea, vomiting, urticaria whereas in FCM group only 6% developed 
nausea,giddiness and arthralgia. 
 
IRON SUCROSE FCM 
7 3 
 
 
0
1
2
3
4
5
6
7
IRON SUCROSE FCM
SIDE EFFECTS - IRON SUCROSE & FCM
  
 
 
 
 
DISCUSSION 
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DISCUSSION 
 Post-partum iron deficiency anaemia can be 
treated by oral and intravenous iron. With both of these iron therapies 
hemoglobin levels increase by 2.4 to 4.6 gm/dl. David B et al study has 
shown increase in hemoglobin levels by 2 gm/dl within 7 days and 
4gm/dl within 2-4 weeks in patients receiving ferric carboxymaltose. 
Serum ferritin also increased promptly in IV FCM patients. 
 Giannoulis et al reported increase of 
hemoglobin by 4-6 gm/dl in patients receiving iron sucrose. Setu 
Rathod et al has showed increased in hemoglobin 0f about 2.4gm/dl 
and 3.4 gm/dl at 2 weeks and 6 weeks respectively. In our study 
hemoglobin level increased by 1.65 gm/dl;2.35g/dl in iron sucrose 
group and 2.04 gm/dl;2.83g/dl from FCM group at 2 weeks and 4 
weeks of post treatment. 
 Seid et al reported that ferritin level increases in 
6 weeks about 238 ng/ml in FCM group while there was reported that 
an increase in serum ferritin in oral iron group as 21ng/ml. Christian 
breymann et al  serum ferritin from 39.9 ng/ml from baseline to 568.2 
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ng/ml at week 1, 161.2ng/ml at 12 weeks (p<.001 when compared to 
margin increase in ferritin level with ferrous sulphate group 32.4 from 
baseline to 34.8ng/ml and 43.3ng/ml at 2 weeks and 12 weeks 
respectively. Prasanth S Kharde et al showed that mean increase in 
serum ferritin level from11.47ng/ml from baseline to 47.69 ng/ml at 2 
weeks and 53.47 ng/ml at 6 weeks. In our study the mean improvement 
in serum ferritin level from baseline of 37.12 ng/ml to 113.61 ng/ml at 
4 weeks following iron sucrose and among FCM group there is 
improvement from31.5 ng/ml of baseline to 130.8 ng/ml at 4 weeks. 
  Van Wyck et al has shown a significant 
increase in MCV among FCM patients. Dede et al had shown increase 
in mean MCV of 33.3 fl from pretreatment following iron sucrose 
therapy. Khurshid shabir Raja et al had shown a mean increase in MCV 
0f 10 fl from baseline. Our study shows mean improvement in MCV 
following iron sucrose therapy is from 80.12 fl to 85.44 fl at 4 weeks 
and among FCM group the mean increase is 88.18 fl at 4 weeks from 
78.94 fl. 
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 There is no serious adverse reactions among the 
iron sucrose as well as FCM groups. The incidence of adverse effects 
reported so far is between 6.8% and 24.2%. in our study there is milder 
adverse reactions like nausea, giddiness and urticarial was reported 
with incidence of 6% among FCM group and 14% in iron sucrose 
group. 
 
 
 
 
 
 
 
  
 
 
 
SUMMARY 
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SUMMARY 
 In this study I randomly selected 100 postnatal 
women with IRON DEFICIENCY ANAEMIA with haemoglobin level 
between 8 to 10 gm. Iron deficit is calculated using formula with the 
aim of target haemoglobin 12gm.After getting the consent, and after 
explaining the risks and benefits, 50 postnatal women received iron 
sucrose and 50 women received FCM. The dose required is almost 
1000mg in both the groups. For iron sucrose per sitting only 200mg can 
be administered. So patients in iron sucrose group needs at least five 
visits to receive the required dose. Whereas in FCM group 1000 mg can 
be administered as a single dose.  The outcomes are compared and 
analysed using paired T test and by Independence T test. The 
investigations used are haemoglobin, serum ferritin, blood indices, and 
peripheral smear before and after treatment. The results are 
summarized below. 
 In age and parity the incidence of iron 
deficiency anaemia in both groups were comparable and is more among 
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young age group (15-25) and in multiparas .People belonging to low 
socioeconomic group is also at increased risk. 
 The average increase in haemoglobin in FCM 
group is faster and greater. The average haemoglobin increase is about 
10.92( 2.35g/dl) at 4 weeks in iron sucrose group from baseline value 
of 8.57g where as in FCM group Hb increase is about 11.37(2.83g/dl) 
from 8.54. MCV increases about 85.44(fl) from baseline of 80.12(fl) in 
iron sucrose group whereas in FCM it increases to about 88.18(fl) from 
78.94.So there is significant improvement in blood indices following 
FCM injection.Among iron sucrose group serum ferritin increases from 
baseline (37.2 to 199.98 at 2weeks; 113.61 at 4 weeks). But the 
improvement is greater among FCM GROUP.(31.5 to 266.02 at 2 
weeks and 130.8 at 4 weeks).the ferritin fall at 4th week is due to iron 
redistribution in haemoglobin formation. 
 Adverse reactions following both groups were 
milder .Following iron sucrose 14%(n=7)  developed side effects like 
nausea, vomiting, urticaria whereas in FCM group only 6% developed 
nausea, giddiness and arthralgia. 
 CONCLUSION 
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CONCLUSION  
 This study compared the efficacy of ferric 
carboxymaltose over iron sucrose in the management of postnatal iron 
deficiency anaemia.Though our results showed  improvement in 
hemoglobin, serum ferritin, and blood indices in both iron sucrose and 
FCM group but it was faster and greater with ferric caboxymaltose 
when compared with iron sucrose. Other advantages are more dose can 
be administered at a single visit and the hospitalization duration of the 
patients are reduced greater. The quality of life is also better with FCM 
group. FCM lacks dextran and less immunogenic so adverse reactions 
are also low. So out of two intravenous iron FCM seems to be clinically 
better and statistically significant than iron sucrose in treatment of 
postnatal iron deficiency anaemia 
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ANNEXURES 
  
ANNEXURES 
ABBREVIATIONS: 
IS – Iron Sucrose 
FCM – Ferric carboxymaltose 
TIBC – Total iron binding capacity 
Tfr – Transferrin  
ZPP – Zinc protoporphyrin 
MCV -  Mean Corpuscular Volume. 
MCH – Mean Corpuscular Haemoglobin 
MCHC – Mean Corpuscular Haemoglobin Concentration. 
PCV – Packed cell volume. 
IDA – Iron Deficiency Anaemia. 
Hb – Haemoglobin 
JVP – Jugular Venous Pulse 
ICMR – Indian Council of Medical Research 
SD – Standard Deviation 
LP – Lacerated Perineum 
VBAC – Vaginal Birth After Caesarean 
LSCS – Lower Segment Caserean Section 
ST – Sterilisation 
IV – Intravenous. 
WHO – World Health Organisation. 
 
KEY TO MASTER CHART: 
MOD – Mode of Delivery 
P1L1 – Para 1, Live 1 
PS – Peripheral Smear 
M.H.A-Microcytic Hypochromic Anaemia. 
SE – Side Effects 
P – Present 
A- Absent  
PROFORMA: 
                                                                                                                            DATE: 
NAME:                                                                                     AGE:   
IP NO:  
SOCIOECONOMIC CLASS: 
RELIGION: 
OCCUPATION: 
DOA: 
DOS: 
DOD:                                                  
ADDRESS & CONTACT NO:     
                                                                       
PRESENTING COMPLAINTS:   
 
MENSTRUAL HISTORY:                 
 
MARITAL HISTORY:       
 
OBSTETRIC HISTORY:     
                                           
CONTRACEPTION HISTORY: 
 
PAST MEDICAL HISTORY: 
 
PAST SURGICAL HISTORY: 
 ANY MEDICATIONS:  
 
FAMILY HISTORY:   
                                   
GENERAL EXAMINATION: 
                                           
VITALS:   PULSE RATE 
                RESPIRATORY RATE 
                BLOOD PRESSURE 
RESPIRATORY SYSTEM: 
 
CARDIOVASCULAR SYSTEM: 
 
ABDOMINAL EXAMINATION: 
 
PER VAGINAL EXAMINATION: 
 
INVESTIGATIONS: 
 
COMPLETE BLOOD COUNT: 
 
PERIPHERAL SMEAR:      SR.FERRITIN: 
 
 
CONSENT FORM 
 
I agree to participate in the study entitled “COMPARATIVE 
STUDY OF INTRAVENOUS FERRIC CARBOXYMALTOSE AND 
INTRAVENOUS IRON SUCROSE IN THE MANAGEMENT OF 
POSTNATAL IRON DEFICIENCY ANAEMIA” 
 
I confirm that I have been told about this study in my mother 
tongue and have had the opportunity to clarify my doubts. 
 
I understand that my participation is voluntary and I may refuse 
to participate at any time without giving any reasons and without 
affecting my benefits. 
 
I agree not to restrict the use of any data or results that arise from 
this study. 
 
 
Name of the participant: 
Sign / Thumb print: 
Name of the investigator: Dr. V.Arulmozhi 
Sign of Investigator: 
 
 
சுய ஒப்புதல் படிவம் 
 
இரத்த ச ோகை உள்ள பிர வித்த தோய்மோர்ைளுக்கு ஃ பபரிக் ைோர்போக்ஸி மோல்ச ோஸ் மற்றும் 
ஐயர்ன் சுக்சரோஸ் ஆைியவற்றின் ஒப்படீு பற்றிய ஆய்வு. 
ஆய்வோளர் :மரு.  வவ. அருள்வமொழி, முதுநிகை பட்  சமற்படிப்பு மோணவர், 
  மைப்சபறு மற்றம் பபண்ைள் நைத்துகற 
  ஆர்.எஸ்.ஆர்.எம்.மருத்துவமகை,  
ஸ் ோன்ைி மருத்துவ ைல்லூரி – ப ன்கை 
        
பபயர் :           வயது :        உள்ளிருப்பு எண் : 
 இந்த மருத்துவ ஆய்வின் விவரங்ைள் எைக்கு விளக்ைப்பட் து என்னுக ய 
 ந்சதைங்ைகள தீர்க்ைவும் அதற்ைோை தகுந்த விளக்ைங்ைகள பபறவும் வோய்ப்பளிக்ைப்பட் து 
 நோன் இவ்வோய்வில் தன்ைிச்க யோைத்தோன் பங்சைற்ைிசறன். எந்த ைோரணத்திைோலும் எந்த 
ைட் த்திலும் எந்த  ட்  ிக்ைலும் இன்றி இந்த ஆய்விைிருந்து விைைிக் பைோள்ளைோம் என்றும் 
அறிந்து பைோண்ச ன். 
 நோன் ஆய்விைிருந்து விைைிக்பைோண் ோலும் ஆய்வோளர் என்னுக ய மருத்துவ 
அறிக்கைைகள போர்ப்பதற்சைோ அல்ைது உபசயோைிக்ைசவோ என் அனுமதி சதகவயில்கை எைவும் 
அறிந்து பைோண்ச ன் என்கை பற்றிய தைவல்ைள் ரை ியமோை போதுைோக்ப்படும் என்பகதயும் 
அறிசவன். 
 இந்த ஆய்வின் மூைம் ைிக க்கும் தைவல்ைகளயும் பரிச ோதகை முடிவுைகளயும் 
ஆய்வோளர் அவர் விருப்பத்திற்சைற்ப பயன்படுத்திக் பைோள்ளவும் அதகை பிரசுரிக்ைவும் 
முழுமைது ன்  ம்மதிக்ைிசறன். 
 இந்த ஆய்வில் பங்கு பைோள்ள ஒப்புக்பைோள்ைிசறன் எைக்கு பைோடுக்ைப்பட்டுள்ள 
அறிவுகரைளின்படி ந ந்து பைோள்வது ன் ஆய்வோளருக்கு உண்கமயு ன் இருப்சபன், என்றும் 
உறுதி அளிக்ைிசறன். 
 உ ல்நைம் போதிக்ைப்பட் ோசைோ வழக்ைத்திற்கு மோறோை ஏசதனும் சநோய்குறி 
பதன்பட் ோசைோ அதகை பதரிவிப்சபன் என்றும் உறுதி கூறுைிசறன். 
 இந்த ஆய்வில் எைக்கு எவ்விதமோை பரிச ோதகைைகளயும்  ிைிச்க ைகளயும் 
சமற்பைோள்ள நோன் முழுமைது ன்  ம்மதிக்ைிசறன். 
 
                                              இப்படிக்கு, 
 
ஆய்வோளரின் கைபயோப்பம்                                       சநோயோளியின் கைபயோப்பம் 
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